From Orleans, LA comes the news that the first trial against the medication, Xarelto, will be held in early 2017. Others are due to follow. There is a huge portfolio of xarelto claims against the maker, Jannssen Pharmaceuticals Inc., and Bayer, which are still pending. The number of cases is nearly 14,000.
The plaintiffs allege that Xarelto caused blood to thin so much that it caused serious complications to patients. As there was no antidote to the blood thinner’s power, it caused serious harm. The first plaintiff to have his trial states that he was prescribed the medication for atrial fibrillation or Afib in early 2014. One month later he was in the hospital with bleeding so severe he required many blood transfusions.
He claims the makers mislead the public about the medication’s safety. They also failed to indicate the dangers of the drug to the medical community or to the US Food and Drug Administration. They only referenced certain results from clinical trials to get the pill on the market. The issues of the medication were not disclosed.
Xarelto was compared with its rival medication, Warfarin is also known generically as Coumadin. This medication requires routine blood tests and dietary restrictions of the patients who take it. Xarelto came out as being a much easier medication to take with as much safety and effectiveness as Warfarin.
There were tests done on the two and allegations were made against the readings taken of patients by Inratio. It was believed the readings showed patients in a control group taking too much Warfarin thereby casting a better light on the Xarelto. The FDA feels that any variations in the readings done by Inratio were too slight to skew the results for Xarelto. Originally, Xarelto was approved for DVT or deep vein thrombosis.
Eventually, Xarelto was introduced to the market to be a better, easier way of managing Warfarin patients. It seemed to be too ineffective at reducing the risks of DVT or stroke from atrial fibrillation. It helped manage the levels of Warfarin used. Too much of the Warfarin itself risked hemorrhages, and bleeding.
In their xarelto claims, plaintiffs made note of the lack of an antidote available to combat the excess Xarelto bleeding. With Warfarin, patients are taken care of with a vitamin K infusion. The treatment does not work on Xarelto, leaving it to be a risky medication. Plaintiffs further claim that the makers of Xarelto were irresponsible for claiming that Xarelto required no monitoring. Because it did not have a reversing agent, the opposite became true.
Xarelto came on the market with big expectations. In the first year on the market, it brought in close to $600 million. By the end of 2013, it yielded $2 billion. The future of the drug remains to be seen as these xarelto claims lawsuits come to trial.